ev-a71

EV-A71-IN-3 (Compound IRE-03-3) is an inhibitor of the enterovirus A71 (EV-A71). It targets the internal ribosome entry site (IRES) of EV-A71, blocking IRES-mediated translation and thereby preventing viral proliferation, with an EC50 of 11.96 μM.

EV-A71-IN-1 is a potent inhibitor of the human enterovirus A71 (EV-A71) capsid protein, with an EC50 of 0.27 μM against EV-A71. Acting as a capsid binder, EV-A71-IN-1 disrupts the crucial interaction between the viral VP1 protein and the host receptor hSCARB2. It displays broad-spectrum antiviral activity against various human enteroviruses, while being non-toxic to human cells (CC50 > 56.2 μM) [1].

EV-A71-IN-2 (compound 6c) is an antiviral agent targeting Enterovirus A71, exhibiting EC50 values of 0.29 μM in EV-A71-MRC-5 cells and 1.66 μM in EV-A71-RD cells. It is utilized in research focused on Enterovirus infections.

LY2334737 is an orally available prodrug of gemcitabine with antineoplastic activity.

HR-568 displays broad-spectrum anti-enterovirus activity. It inhibits enterovirus strains EV-A71, E30, and CVA24 in MRC-5 cells, with EC50 values of 1.53 μM, 0.4 μM, and 1.22 μM, respectively. HR-568 targets the hydrophobic pocket on enterovirus capsid proteins, thereby hindering viral replication.

Dyrk1A-IN-12 (compound S43) is an inhibitor of dual specificity tyrosine phosphorylation regulated kinase 1A (Dyrk1A). It has an IC50 of 95 nM for inhibiting Dyrk1A. The compound demonstrates antiviral activity against EV-A71 (Enterovirus A71) with an EC50 of 4.4 μM, a CC50 of 12.8 μM, and a selectivity index (SI) of 2.9. Additionally, Dyrk1A-IN-12 exhibits potent inhibitory effects on the herpes simplex virus (HSV).

Viral 2C protein inhibitor 1 (compound 6aw) is a potent, broad-spectrum antiviral agent targeting the viral 2C protein, demonstrating relatively low cytotoxicity and a high selectivity index. It effectively inhibits multiple strains of EV-D68, EV-A71, and CVB3 with EC50 values ranging from 0.1 to 3.6 μM [1].

AL-470 demonstrates significant antiviral efficacy, exhibiting EC50 values of 0.27 µM against HIV-1, 0.63 µM against HIV-2, and 0.35 µM against EV-A71, as referenced in [1].

ER-DRI is a potent peptide inhibitor that targets EV-A71. It directly binds to 3A and specifically neutralizes the activity of RNAi virus suppressor factors, thereby unlocking the antiviral RNAi response inhibited by 3A. ER-DRI also effectively inhibits another RNAi-dependent enterovirus, Coxsackievirus A16.